ArticleDrug metabolism and disposition: the biological fate of chemicals2025
Mycobacteriumabscessus CYP123 is a steroid hydroxylase with an implication in host infection.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium abscessus (Mab, MAB) poses a rising health threat worldwide. Infections occur in hospital settings, affecting immunocompromised and immunocompetent patients alike. Individuals with underlying lung diseases, such as cystic fibrosis and bronchiectasis, are particularly at risk. Mab is intrinsically multidrug resistant to most antibiotics, has high treatment failure to current treatment regimens, and lacks a vaccine. Targeting bacterial metabolism has historically resulted in successful therapies. We discovered that the cytochrome P450 isoform CYP123 encoded by MAB_1216c is required for host infection. To determine the role of CYP123 during host infection, we generated highly active recombinant CYP123 and found CYP123 interactions with steroid hormones, which are key players in host immune response. All tested steroids induced a reverse type I shift when titrated to the enzyme. Their binding affinity was dictated by the presence of hydroxyl groups at certain positions in the steroid scaffold. Metabolism assays with a surrogate redox system revealed that CYP123 is a steroid hydroxylase and can convert 11-deoxycorticosterone and progesterone to a single monohydroxylated product, respectively. Mab infection has been associated with fungal coinfection, and cytochrome P450 enzymes have been shown to interact with azoles. We found that CYP123 binds to various triazole and azole drugs in the low micromolar range. Our results indicate that Mab CYP123 can interfere with host endobiotics with a potential implication in host cell reprogramming and can bind antifungal therapeutics possibly leading to worse polymicrobial infections. CYP123 could emerge as a potential drug target for an orthogonal approach to treating Mab infections. SIGNIFICANCE STATEMENT: Infections with the pathogen Mycobacterium abscessus are on the rise with limited treatment options. The M. abscessus cytochrome P450 CYP123 was identified to play an essential role for host infection. Steroids do not only bind to CYP123 but are also metabolized to monohydroxylated products implicating the potential to interfere with steroidogenesis and immune antagonism by this bacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.